$SYK

Fletcher Robert S sold $39K of SYK

Fletcher Robert S (VP, Chief Legal Officer) sold 125 shares of STRYKER CORP (SYK) at $310.22 on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fletcher Robert S
Published May 29, 2026, 8:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SYK
Neutral
high confidence
Mentioned
$SYK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYKNeutralLow
01

Why it matters

A routine 10b5-1 sale is generally not a standalone catalyst; traders may only note it for sentiment/positioning and to confirm no other concurrent fundamental news.

02

Market read

Low incremental information for SYK; more useful as a data point than a catalyst.

03

What to watch

The filing does not indicate size relative to total holdings beyond the post-transaction count; without trend context (multiple prior Form 4s), inference is limited.

Relevance 3/10Novelty 2/10Timing: Filed 2026-05-29; sale executed 2026-05-28 under a 10b5-1 plan.

Background

The article is an SEC Form 4 insider transaction disclosure (officer/direct holdings) for Stryker.

Company-level read

Ticker impact

$SYKNeutralHigh confidence
Context

Stryker (SYK) disclosed an insider open-market sale by its Chief Legal Officer: 125 shares sold at $310.22 on 2026-05-28 under a 10b5-1 plan.

Expected impact

Likely minimal near-term price impact; any effect is more sentiment/flow-related than fundamental.

Evidence & confidence

The filing specifies a Rule 10b5-1 pre-arranged plan and a small, routine officer sale; no earnings, guidance, or operational change is reported.

Market effects

No clear sector read-through; this is company-specific insider transaction disclosure without new sector/regulatory facts.

None indicated.

None indicated.

Counterpoint

Insider sales can sometimes coincide with private information, but the 10b5-1 designation materially reduces that signal.

Key entities

  • STRYKER CORP

    Issuer of the reported Form 4 insider sale by its Chief Legal Officer.

  • Fletcher Robert S

    VP, Chief Legal Officer who sold 125 shares under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SYKHighAI 8/10

Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS

Stryker (SYK) shares fell $26.70 (-8.8%) on Sept. 8, 2026, after its CFO revealed persisting manufacturing issues in its Peripheral Vascular unit, acquired from Inari Medical. The firm Hagens Berman is investigating potential disclosure violations. The issue, initially thought resolved, led to lost sales and backorders, with the CFO stating it will continue into Q4.

$SYKLow

Why Stryker (SYK) Stock Is Down Today

Stryker (SYK) shares fell 6.9% after management at a healthcare conference indicated longer-than-expected supply chain issues and slower joint replacement recovery, potentially affecting revenue. The company had reported solid Q2 results in July. Insider sales and mixed hedge fund activity were also noted.

$SYKMed

Stryker stock drops 7.7% as supply problems and weak joint replacement sales hit outlook

Stryker shares dropped 7.7% on Tuesday due to ongoing supply chain issues and weaker-than-expected joint replacement sales. CFO Preston Wells stated that manufacturing problems will persist into Q4, impacting sales growth. The company also missed recovery expectations in its joint replacement business, citing seasonal weakness. Investors are concerned about the timing of a broader recovery.